Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2017	$ 80,867,162	$ 167,155	$ 514,037,301	$ 33,232	$ (432,815,338)	$ (555,188)
Beginning Balance, Shares at Sep. 30, 2017		74,785,426
Stock-based compensation	8,454,607		8,454,607
Exercise of stock options, Amount	2,656,710	$ 605	2,656,105
Exercise of stock options, Shares		604,611
Exercise of warrants, Amount	1,237,429	$ 288	1,237,141
Exercise of warrants, Shares		288,473
Common stock - restricted stock units vesting, Amount	(54,668)	$ 1,327	(55,995)
Common stock - restricted stock units vesting, Shares		1,326,792
Common stock - issued for cash, Amount	56,585,035	$ 11,500	56,573,535
Common stock - issued for cash, Shares		11,500,000
Foreign currency translation adjustments	(54,796)			(54,796)
Net income (loss)	(54,450,478)				(54,450,478)
Ending Balance, Amount at Sep. 30, 2018	95,241,001	$ 180,875	582,902,694	(21,564)	(487,265,816)	(555,188)
Ending Balance, Shares at Sep. 30, 2018		88,505,302
Stock-based compensation	12,393,323		12,393,323
Exercise of stock options, Amount	8,275,410	$ 1,543	8,273,867
Exercise of stock options, Shares		1,542,795
Common stock - restricted stock units vesting, Amount		$ 2,197	(2,197)
Common stock - restricted stock units vesting, Shares		2,197,305
Common stock - issued for cash, Amount	60,521,729	$ 3,261	60,518,468
Common stock - issued for cash, Shares		3,260,869
Foreign currency translation adjustments	(370,060)			(370,060)
Net income (loss)	67,974,849				67,974,849
Ending Balance, Amount at Sep. 30, 2019	244,036,252	$ 187,876	664,086,155	(391,624)	(419,290,967)	(555,188)
Ending Balance, Shares at Sep. 30, 2019		95,506,271
Stock-based compensation	43,382,988		43,382,988
Exercise of stock options, Amount	$ 7,468,899	$ 1,111	7,467,788
Exercise of stock options, Shares	1,111,128	1,111,128
Common stock - restricted stock units vesting, Amount		$ 1,159	(1,159)
Common stock - restricted stock units vesting, Shares		1,158,904
Common stock - issued for cash, Amount	$ 250,478,974	$ 4,600	250,474,374
Common stock - issued for cash, Shares		4,600,000
Foreign currency translation adjustments	410,057			410,057
Deconsolidation of Ablaris Therapeutics, Inc.	555,188					$ 555,188
Net income (loss)	(84,553,226)				(84,553,226)
Ending Balance, Amount at Sep. 30, 2020	$ 461,779,132	$ 194,746	$ 965,410,146	$ 18,433	$ (503,844,193)
Ending Balance, Shares at Sep. 30, 2020		102,376,303